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Summary
 Background: Reports published in the past several years have not provided conclusive evidence regarding a re-
lationship between the development of colorectal cancer and NOD2 gene mutations, though some 
geographic variability has been shown.
 Material/Methods: The goal of the current project was to analyze the frequency of selected NOD2 gene variants, in-
cluding P286S, R702W, G908R, and 1007fs, in the Polish population of patients with rectal can-
cer. Fifty-one rectal cancer patients undergoing treatment were included in the study. As a control 
group to provide a reference point for NOD2 polymorphism in the population, DNA obtained from 
cord blood collected from the placenta of 100 patients immediately after parturition was used.
 Results: It was found that the aforementioned mutations were more frequent among the colorectal cancer 
patients and that the presence of the 1007fs variant might also be associated with young patient 
age.
 Conclusions: The analysis of the material does not allow presenting a conclusive answer as to whether the 1007fs, 
G908R, and R702W mutations or P268S polymorphism contribute to the development of sporadic 
colorectal cancer in the Polish population. Patients in some populations could likely benefi t from 
instituting earlier colorectal cancer screening studies following the detection of the 1007fs muta-
tion.
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In 2001, two independent research groups reported that 
NOD2-encoded protein participates in innate immunity [1,2]. 
This system regulates responses to pathogenic microorgan-
isms in humans and other mammalian species. The system 
was initially thought to be stimulated via the recognition of 
specifi c pathogens by receptors present on the surface of 
immune cells. This theory was revised upon the discovery 
of NOD2 on chromosome 16q12, followed by the identifi ca-
tion of an entire family of NOD2-related genes. NOD1 and 
NOD2 proteins were found to act as, among others, intra-
cellular receptors of bacterial proteins and participate in 
nonspecifi c immune responses through activation of the 
nuclear factor kB [3]. Finally, it was particularly surprising 
that the structure of NOD1 and NOD2 was homologous to 
that of Apaf-1 protein (which serves as an apoptosis regu-
lator) and of plant R polypeptides, gene products under-
lying the innate immunity of plants to pathogenic micro-
organisms [4]. The highly conservative structure of NOD2 
refl ects the prominent role played by this molecule in hu-
mans and animals: a murine homolog of this protein dis-
plays over 80% similarity to human NOD2.
NOD2 consists of three domains. Two CARDs (caspase recruit-
ment domains) are located at the N-terminus, one nucleotide-
binding NOD (nucleotide oligomerization domain) is in the 
middle, and eleven repetitive leucine-rich amino-acid sequenc-
es (dubbed LRR for leucine-rich repeats) occupy the C-termi-
nus of the polypeptide. NOD1 shares structural similarity with 
NOD2; however, the fi rst contains one CARD whereas the lat-
ter has two. More recent publications frequently refer to NOD1 
and NOD2 proteins as CARD4 and CARD15 [4,5].
In medicine, NOD2 mutations are generally strongly asso-
ciated with the pathogenesis of Crohn’s disease. Regional 
(distal) ileitis appears to be a complex disorder stemming, 
among others, from genetic abnormalities. The frameshift 
mutation (Leu1007fs) and two other nonsense mutations 
(Gly908Arg and Arg702Trp) of NOD2 increase the risk in 
their carriers of developing this disease: this chance is 2–4 
times higher in heterozygotes and even 20–30 times high-
er in homozygotes [1,2].
A different issue is an association between NOD2 mutations 
and the process of oncogenesis. Lubinski et al. (2005) ana-
lyzed the frequency of the Leu1007fs mutation in a Polish 
population of healthy volunteers versus subjects suffer-
ing from one of twelve types of cancer. This mutation was 
found to be very common, as approximately 7% of the con-
trol subjects were its carriers. Among patients diagnosed 
with cancer of the thyroid gland, stomach, ovary, larynx, 
lungs and, primarily, breast and colorectum, the percent-
age of 3020insC mutation carriers ranged from 9.4 (stom-
ach) to 12.2 (colorectum) and even 14.3% (the DCIS form 
of breast cancer) [6].
The aforementioned correlations, although not well estab-
lished in the current body of literature, led us to analyze the 
link between selected changes in the NOD2/CARD15 gene 
and colorectal cancer (adenocarcinoma). According to the 
Polish National Cancer Registry, this is second most com-
mon type of cancer (after lung cancer) in the Polish pop-
ulation. In 2005 there were 13,987 new cases of colorectal 
cancer in Poland. In 44% of those cases (6094) the cancer 
was located within the distal colon, from the rectosigmoid 
junction to the anus. Independent research of this type of 
malignant colonic neoplasm seems to be justifi ed taking 
into account distinct diagnostic methods, different therapy 
approaches, and, consequently, prognosis.
MATERIAL AND METHODS
Fifty-one patients of the Cancer Genetics Clinic, District 
Hospital, Toruń, Poland, diagnosed with rectal adenocar-
cinoma were included in the study. This group consisted of 
patients diagnosed with rectal cancer in 2005 and 2006 who 
accepted the invitation to join the study. Overall, 60 invita-
tions were sent, which gives an acceptance rate of 87%. As 
a control group providing a reference point for the NOD2 
polymorphism in the population, we used DNA obtained 
from cord blood collected from the placenta of 100 patients 
(Obstetrics, Feminine Health, and Oncologic Gynecology 
Unit, District Hospital, Toruń, Poland) immediately after 
parturition. All persons included in the study were ethnic 
Poles. The study was approved by the Nicolaus Copernicus 
University Bioethics Committee at the Collegium Medicum 
in Bydgoszcz (No. KB/174/2006).
The P286S, R702W, G908R, and 1007fs mutations were an-
alyzed. The PCR-RFLP technique was utilized to establish 
P286S polymorphism as well as the R702W and G908R muta-
tions. The presence of the 1007fs NOD2 mutation was deter-
mined with the allele-specifi c amplifi cation (ASA) technique 




All the investigated variants of the NOD2 gene were pres-
ent in the control group. P268S polymorphism was detect-
ed In 30 of the 100 persons (30%), the R702W mutation 
in 4 persons (4%), G908R mutation in two s (2%), and the 
1007fs mutation in 7 (7%).
P268S Polymorphism
Twenty-seven (52.9%) of the 51 colorectal cancer patients 
were P268S polymorphism carriers in the NOD2 gene. These 
included 9 females and 18 males. Three males and one fe-
male had this polymorphism in two alleles of the gene. The 
average age of the polymorphism carriers was 62.6 years, in 
females 66.6 years and in males 60.6 years. The differences in 
frequency of the 268S allele between the study group and con-
trols (Figure 1) were statistically signifi cant (OR=2.61, p=0.0078; 
R language, Bonferroni correction for multiple testing of the 
same data (in this case: four times), statistically signifi cant when 
p<0.05/4=0.0125). However, P268S polymorphism also accom-
panies the three other mutations studied. The comparison of 
cases when the mutation of interest was not accompanied by 
any of the others did not yield any signifi cant differences.
R702W mutation
Six (11.7%) of the 51 colorectal adenocarcinoma patients 
were carriers of the R702 mutation in the NOD2 gene. These 
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included 2 females and 4 males. One male had this mutation 
in both alleles of the gene. The average age of the mutation 
carriers was 66.16 years, in females 64 years and in males 
67.25 years. All R702W mutation carriers were also P268S 
polymorphism carriers. The two-tailed Fisher’s test showed 
that the increase in 702W allele frequency in colorectal can-
cer patients compared with controls was not statistically sig-
nifi cant (OR=3.17, p=0.09, greater than the Bonferroni-cor-
rected p of 0.0125 and even greater than 0.05) (Figure 1). 
It was shown, however, that in persons aged 65 or older (21 
individuals in the group studied, including 4 mutation car-
riers) the difference in the frequency of the mutation of in-
terest was statistically signifi cant (OR=4.96, p=0.04), though 
the Bonferroni correction negates this conclusion.
G908R mutation
Two (3.9%) of the 51 colorectal cancer patients were carri-
ers of the G908R mutation in the NOD2 gene. These includ-
ed one male and one female. The age of the female muta-
tion carrier was 82 years and of the male 55 years (Table 1). 
All G908R mutation carriers were also P268S polymorphism 
carriers. The G908R mutation-containing NOD2 allele was 
more frequent in the study group than in controls (OR=1.99, 
Figure 1); however, Fisher’s test did not show signifi cance 
between the observed values (p=0.6).
1007fs mutation
Five (9.8%) of the 51 colorectal adenocarcinoma patients 
were carriers of the 1007fs mutation in the NOD2 gene. 
These included 3 females and 2 males. The characteristic 
feature of this group was a signifi cantly lower patient age 
when diagnosed with cancer. It was 50.6 years, on average 
12.5 years lower than for the entire group studied. One pa-
tient with this mutation (female patient #5) already under-
went surgery at the age of 39. All 1007fs mutation carriers 
were also P268S polymorphism carriers. A relatively high-
er frequency of the 1007fs allele was observed in the study 
group than in the controls (Figure 1, OR=1.44). The two-
tailed Fisher’s test showed that the increase in 1007fs allele 
frequency in the operated patients compared with the con-
trols was not statistically signifi cant. In the colorectal patients 
aged 56 years or older (17 individuals, including 5 carriers) 
there was a signifi cant increase in the frequency of this mu-
tation (OR=5.41, p=0.015). Bonferroni correction does not 
support the conclusion that the observed frequency differ-
ences are signifi cant (p>0.0125, Table 1).
DISCUSSION
In eukaryotes, nuclear factor kB, whose activity is regulated 
by, among others, NOD2 protein, plays an essential role in 
the regulation of basic processes of the organism, including 
immune response, apoptosis, cell cycle control, and the de-
velopment of individual cell lines [7]. Due to its crucial in-
volvement in the regulation of cell division mechanisms, it 
was attributed with an uncertain role in the process of can-
cer development, where its activity is signifi cantly elevat-
ed. Already in the mid-1990s its importance was described 
in relation to cancer of the thyroid, breast, lung, and col-
orectum [8–11].
The most recent data leave no doubt that alterations in the 





















Figure 1.  NOD2 allele frequency in patients suff ering from rectal 
cancer (dark gray) and healthy controls (gray). OR – ratio 
of the chance of observing the mutated allele in cancer 
patients and the chance of observing the same mutated 
allele in healthy controls. The ”P268S only” group includes 
those individuals who showed only P268S polymorphism 
and none of the studied mutations.
Test type P268S R702W G908R 1007fs
Number of persons with the mutation  27.0  6.0  2.0  5.0
Number of women with the mutation  9.0  2.0  1.0  3.0
Number of men with the mutation  18.0  4.0  1.0  2.0
% of persons with the mutation  52.9  11.7  3.33  9.8
% of women with the mutation  42.85  9.52  4.76  14.28
% of men with the mutation  60.0  13.33  3.33  6.66
Average age of persons with the mutation  62.6  66.16  68.5  50.6
Average age of women with the mutation  66.6  64.0  82.0  49.0
Average age of men with the mutation  60.6  67.25  81.0  53.0
Table 1. The numbers, percentages, and average ages of patients suff ering from rectal cancer and displaying the NOD2 gene mutations.
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ry Crohn’s disease, though reports to the contrary do spo-
radically surface. NOD2 involvement in the development of 
colorectal cancer appears more dubious, although Crohn’s 
disease itself is a recognized pre-cancer state [12]. One of the 
fi rst reports defi ning the importance of NOD2 mutation in 
oncogenesis was the publication by Lubinski et al. describ-
ing a correlation between the 1007fs NOD2 mutation and 
an elevated risk of colorectal cancer in older people (over 
50 years old) [13]. Those observations were not confi rmed 
by other studies. Alhopuro et al. analyzed a large popula-
tion of over 1000 Finnish patients and found that the 1007fs 
mutation could not by itself be regarded as a factor accom-
panying an increased risk of colorectal cancer and that the 
statistically signifi cant elevated frequency of the mutation 
in Polish people aged 50 and over could not be reproduced 
in Finns [14]. There were attempts to explain this phenom-
enon through the heterogeneity of mutations, some envi-
ronmental factors, and other oncogenesis-related phenom-
ena within the European population [14,15].
Our studies aimed at a more thorough clarifi cation of this 
issue. We analyzed the potential infl uence of the most fre-
quently described NOD2/CARD15 gene mutations, namely 
1007fs, G908R, and R702W as well as P268S polymorphism, 
on the occurrence of only rectal cancer. These mutations 
had been examined prior to this study and analyses of sim-
ilar relationships have been performed (Zaahl et al.), al-
though they concerned only classical cases of intestinal in-
fl ammatory diseases (ulcerative colitis and Crohn’s disease). 
The studies were of epidemiological nature and their re-
sults were not corroborated by statistically signifi cant fi nd-
ings in other populations, including in South Africa [16]. 
The authors noted primarily a low frequency (<20%) of the 
aforementioned alterations in the gene, which confi rmed a 
variability in the geographic distribution of the mutations. 
Similar studies were performed by a group of researchers 
in New Zealand who unequivocally showed that the combi-
nation of three of the mutations described above, namely 
R702W, G908R, and 1007fs, is associated with an increased 
frequency of sporadic colorectal cancer in the population, 
though no link with age and tumor dynamics was defi ned 
[17]. This was one of the fi rst reports delineating the im-
portance of the above-mentioned NOD2 alterations in on-
cogenesis.
In the current study we found that P268S was the most com-
mon form of NOD2/CARD15 polymorphism; we detected 
it in more than half of patients suffering from colorectal 
adenocarcinoma (52.9%) and it was always present when 
one of the remaining mutations was demonstrated. This 
corroborates the hypothesis put forth by Bonen et al. that 
this variant exhibits profound activity in various intestinal 
diseases [18]. This polymorphism by itself, as a lone alter-
ation, did not prove to have a statistically signifi cant im-
pact on cancer development. It was one of the fi rst reports 
on the aforementioned changes within the NOD2 gene as 
an underlying cause in oncogenesis. This relationship was 
not corroborated by the fi ndings in several European pop-
ulations. Lakatos et al. did not observe a correlation be-
tween clinical characteristics and the frequency of sporad-
ic colorectal cancer (CRC) and selected NOD2/CARD15 
variants in the Hungarian population [18]. Furthermore, 
data obtained by Tupanen and colleagues in 1042 Finnish 
CRC patients did not show a link between the R702 and 
G908R mutations and contradicted the earlier fi ndings in 
the Finnish population [19].
We observed that P268S was the most frequently occurring 
NOD2/CARD15 polymorphism as it was present in more 
than half of colorectal adenocarcinoma cases (52.9%) and 
was always found when any of the remaining mutations ex-
isted. This may support the notion put forth by Bonen et 
al. that this variant displays a vast array of actions in various 
intestinal diseases [20]. By itself, this polymorphism did not 
turn out to have a statistically signifi cant effect on the devel-
opment of cancer, nor did the remaining mutations within 
the NOD2 gene. As visualized through statistical analyses, 
the 1007fs and R702W mutations do not seem to affect can-
cer development. These two changes have been previous-
ly associated with the severity of the intestinal infl ammato-
ry condition observed in Crohn’s disease, which is thought 
to elevate the risk of colorectal adenocarcinoma develop-
ment. These mutations have also been found to predispose 
the patient to display a more severe course of infl ammatory 
disease with serious complications that typically require sur-
gical intervention [21]. G908R appears to have a similar in-
fl uence, although this mutation also seemed more frequent 
in cancer patients than in controls. The fact that the 1007fs 
mutation is present in relatively young people is an interest-
ing observation. The average age of 50 years in patients be-
longing to this group was much different from that of the 
remaining groups (Table 1). The youngest surgically treat-
ed patient was not yet 40 years old. It is extremely diffi cult 
to explain this phenomenon based on just one study, espe-
cially because thus far this phenomenon has not been sup-
ported by statistics, and only one publication (Kurzawski et 
al.) showed a correlation between sporadic cancer with the 
NOD2 mutation and patient age [13]. Although the current 
study does not prove the presumed (in some European pop-
ulations, including the Polish one) relationship between 
composite mutations in the NOD2 gene and colorectal can-
cer, knowledge of this potential but not fully recognized 
correlation may aid, following large population studies, in 
selecting a subgroup of patients who require increased on-
cological alertness and, possibly, earlier endoscopic screen-
ing, similarly to FAP or HNPCC. The geographic variabili-
ty observed in previous epidemiological studies may be an 
obstacle in confi rming this relationship. Therefore, enrich-
ing the patient database with new analyzed cases may likely 
lead to defi ning the geographic range of this potential risk 
of cancer development.
CONCLUSIONS
The analysis of the material does not allow us to present a 
conclusive answer as to whether 1007fs, G908R, and R702W 
mutations as well as P268S polymorphism contribute to the 
development of sporadic colorectal cancer in the Polish 
population. Considering the many contradictory reports, 
this still undefi ned mechanism can be explained only by 
including additional cases in the analysis and performing 
meta-analyses.
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